PT  - JOURNAL ARTICLE
AU  - Wu, Qiong
AU  - Zhang, Bingyu
AU  - Tong, Jiayi
AU  - Bailey, L. Charles
AU  - Bunnell, H. Timothy
AU  - Chen, Jiajie
AU  - Chrischilles, Elizabeth A.
AU  - Christakis, Dimitri A.
AU  - Downs, Stephen M.
AU  - Hirabayashi, Kathryn
AU  - Jhaveri, Ravi
AU  - Mishkin, Aaron D.
AU  - Mosa, Abu S.M.
AU  - Pajor, Nathan M.
AU  - Rao, Suchitra
AU  - Razzaghi, Hanieh
AU  - Schwenk, Hayden T.
AU  - Sills, Marion R.
AU  - Wang, Huiyuan
AU  - Wang, Linbo
AU  - Wang, Yudong
AU  - Zhang, Dazheng
AU  - Zhou, Ting
AU  - Tchetgen Tchetgen, Eric J.
AU  - Morris, Jeffrey S.
AU  - Forrest, Christopher B.
AU  - Chen, Yong
ED  - ,
TI  - Real-world Effectiveness and Causal Mediation Study of BNT162b2 on Long COVID Risks in Children and Adolescents
AID  - 10.1101/2024.02.19.24302823
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.02.19.24302823
4099  - http://medrxiv.org/content/early/2024/02/20/2024.02.19.24302823.short
4100  - http://medrxiv.org/content/early/2024/02/20/2024.02.19.24302823.full
AB  - Background The impact of pre-infection vaccination on the risk of long COVID remains unclear in the pediatric population. Further, it is unknown if such pre-infection vaccination can mitigate the risk of long COVID beyond its established protective benefits against SARS-CoV-2 infection.Objective To assess the effectiveness of BNT162b2 on long COVID risks with various strains of the SARS-CoV-2 virus in children and adolescents, using comparative effectiveness methods. To disentangle the overall effectiveness of the vaccine on long COVID outcomes into its independent impact and indirect impact via prevention of SARS-CoV-2 infections, using causal mediation analysis.Design Real-world vaccine effectiveness study and mediation analysis in three independent cohorts: adolescents (12 to 20 years) during the Delta phase, children (5 to 11 years) and adolescents (12 to 20 years) during the Omicron phase.Setting Twenty health systems in the RECOVER PCORnet electronic health record (EHR) Program.Participants 112,590 adolescents (88,811 vaccinated) in the Delta period, 188,894 children (101,277 vaccinated), and 84,735 adolescents (37,724 vaccinated) in the Omicron period.Exposures First dose of the BNT162b2 vaccine vs. no receipt of COVID-19 vaccine.Measurements Outcomes of interest include conclusive or probable diagnosis of long COVID following a documented SARS-CoV-2 infection, and body-system-specific condition clusters of post-acute sequelae of SARS-CoV-2 infection (PASC), such as cardiac, gastrointestinal, musculoskeletal, respiratory, and syndromic categories. The effectiveness was reported as (1-relative risk)*100 and mediating effects were reported as relative risks.Results During the Delta period, the estimated effectiveness of the BNT162b2 vaccine against long COVID among adolescents was 95.4% (95% CI: 90.9% to 97.7%). During the Omicron phase, the estimated effectiveness against long COVID among children was 60.2% (95% CI: 40.3% to 73.5%) and 75.1% (95% CI: 50.4% to 87.5%) among adolescents. The direct effect of vaccination, defined as the effect beyond their impact on SARS-CoV-2 infections, was found to be statistically non-significant in all three study cohorts, with estimates of 1.08 (95% CI: 0.75 to 1.55) in the Delta study among adolescents, 1.24 (95% CI: 0.92 to 1.66) among children and 0.91 (95% CI: 0.69 to 1.19) among adolescents in the Omicron studies. Meanwhile, the estimated indirect effects, which are effects through protecting SARS-CoV-2 infections, were estimated as 0.04 (95% CI: 0.03 to 0.05) among adolescents during Delta phase, 0.31 (95% CI: 0.23 to 0.42) among children and 0.21 (95% CI: 0.16 to 0.27) among adolescents during the Omicron period.Limitations Observational study design and potentially undocumented infection.Conclusions Our study suggests that BNT162b2 was effective in reducing risk of long COVID outcomes in children and adolescents during the Delta and Omicron periods. The mediation analysis indicates the vaccine’s effectiveness is primarily derived from its role in reducing the risk of SARS-CoV-2 infection.Primary Funding Source National Institutes of Health.Competing Interest StatementDr. Rao reports prior grant support from GSK and Biofire and is a consultant for Sequiris. Dr. Jhaveri is a consultant for AstraZeneca, Seqirus, Dynavax, receives an editorial stipend from Elsevier and Pediatric Infectious Diseases Society and royalties from Up To Date/Wolters Kluwer. Funding StatementThis work was supported in part by National Institutes of Health (OT2HL161847-01, 1R01LM012607, 1R01AI130460, 1R01AG073435, 1R56AG074604, 1R01LM013519, 1R01LM014344, 1R56AG069880, 1R01AG077820, 1U01TR003709, 1R21AI167418, 1R21EY034179). This work was supported partially through Patient-Centered Outcomes Research Institute (PCORI) Project Program Awards (ME-2019C3-18315 and ME-2018C3-14899). All statements in this report, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the Patient-Centered Outcomes Research Institute (PCORI), its Board of Governors, or Methodology Committee.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of the University of Pennsylvania waived ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors